SATMEG Ventures is developing new treatments for solid tumours. The company commercialises research results from the Sahlgrenska Translational Melanoma Group (SATMEG) to provide tailored therapies for melanoma patients.
Impact: Transform advanced cancer research into personalised therapies.
Founder and Chairman: Jonas Nilsson
GUV Contact: Lorna Fletcher
Impact: Transform advanced cancer research into personalised therapies.
Founder and Chairman: Jonas Nilsson
GUV Contact: Lorna Fletcher